PatientPop is the provider of an all-in-one practice growth solution designed to enhance and automate each touchpoint in the patient journey — from first impression online to digital booking to post-visit follow-up — to makes it easy for healthcare providers to attract more patients, manage online reputation, modernize the patient experience, and automate the front office.

Register for Details

For more details on financing and valuation of private companies similar to PatientPop before its M&A, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about PatientPop

To invest in PatientPop pre-IPO

Can you invest in PatientPop pre-IPO?

You can no longer invest in PatientPop with Forge. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of PatientPop before it goes public?

You can no longer sell shares of PatientPop on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my PatientPop shares?

Forge can no longer determine the value of PatientPop shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is PatientPop a publicly traded company?

PatientPop became a public company following its M&A on 11/02/2021 and is now a publicly traded company.

To learn more about PatientPop potential IPO

Will PatientPop go IPO?

PatientPop became a public company following its M&A on 11/02/2021.

What is PatientPop’s IPO price?

The IPO price of PatientPop is not currently available.

When was PatientPop founded?

PatientPop was founded in 2014.

What is PatientPop funding to date?

PatientPop has raised $125.82MM to date.

Who are PatientPop’s major investors?

PatientPop Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/25/2020 Series C-1 $3.39MM $xx.xx $42.59B Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
Price per Share
$xx.xx
Shares Outstanding
341,859
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
08/25/2020 Series C-3 $4.5MM $xx.xx $42.59B Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
Price per Share
$xx.xx
Shares Outstanding
453,400
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
08/25/2020 Series C-2 $5.61MM $xx.xx $42.59B Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
Price per Share
$xx.xx
Shares Outstanding
564,942
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
08/25/2020 Series C $42.65MM $xx.xx $42.59B Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
Price per Share
$xx.xx
Shares Outstanding
4,297,717
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Commonfund, Hlm Venture Partners, Silicon Valley Bank, Toba Capital, Transformation Capital, Vivo Capital
10/22/2018 Series B-2 $5MM $xx.xx $38.58B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
548,846
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
10/22/2018 Series A-5 $10MM $xx.xx $38.58B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
1,321,003
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
10/22/2018 Series B-1 $15MM $xx.xx $38.58B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
1,646,542
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
10/22/2018 Series A-4 $15MM $xx.xx $38.58B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
2,920,390
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
12/29/2016 Series A-3 $4.5MM $xx.xx $14.83B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
1,265,502
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
05/17/2016 Series A-2 $7.57MM $xx.xx $12.12B Athenahealth, Silicon Valley Bank, Toba Capital
Price per Share
$xx.xx
Shares Outstanding
2,599,161
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Athenahealth, Silicon Valley Bank, Toba Capital
11/04/2015 Series A $10.03MM $xx.xx $9.17B Toba Capital
Price per Share
$xx.xx
Shares Outstanding
4,520,473
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Toba Capital
05/13/2015 Series Seed $504,997.00 $xx.xx $2.97B --
Price per Share
$xx.xx
Shares Outstanding
841,661
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
--
05/13/2015 Series Seed-2 $2.05MM $xx.xx $2.97B Athenahealth
Price per Share
$xx.xx
Shares Outstanding
2,828,211
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Athenahealth
Updated on: Nov 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.